BofA Securities Raises Eli Lilly Price Target
BofA Securities analyst Jason Gerberry maintained a 'Buy' rating on Eli Lilly and Company while increasing the price target from $1,497 to $1,557.
Stocks · News reference
Lilly to Present New Clinical Data on Retatrutide, Taltz, and Zepbound at ACR Convergence 2026
Eli Lilly and Company announced it will showcase new clinical and real-world research regarding the use of retatrutide, Taltz, and Zepbound in patients with rheumatologic conditions and obesity.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Zenith Epigenetics Announces Clinical Trial Collaboration with Eli Lilly
Zenith Epigenetics has executed a Clinical Trial Collaboration and Supply Agreement with Eli Lilly to study the combination of ZEN-3694 and Verzenio in patients with NUT carcinoma.
LifeMD Partners with Eli Lilly to Expand Access to GLP-1 Medications
LifeMD has entered into an arrangement with Eli Lilly and Company to enable the direct dispensing and shipping of Lilly's self-pay GLP-1 medications, including Zepbound and Foundayo, to eligible patients.
T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease
T-Therapeutics closed a $133 million Series B funding round co-led by Advent Life Sciences and British Business Bank to advance clinical development of first-in-class TCR-CD3 bispecific therapies for cancer and autoimmune diseases. The company appointed Dr. Kirsty Crame as Chief Development Officer and plans to generate clinical proof-of-concept data for two lead programmes leveraging its proprietary OpTiMus platform.
If the S&P 500 Falls 20%, Here's the 1 ETF I'd Buy Hand Over Fist
The article argues that a 20% decline in the S&P 500 would present a buying opportunity rather than a reason to panic. The author recommends the Vanguard S&P 500 ETF (VOO) as a long-term investment vehicle, citing the S&P 500's 98-year track record of 9.98% annualized returns despite multiple economic crises. The piece emphasizes that while individual stocks can fail, the broader market has consistently recovered and rewarded patient investors.
NAD Recommends Good Life Meds Discontinue Claims for Compounded Tirzepatide
Following a challenge by Eli Lilly and Company, the National Advertising Division recommended that Good Life Meds, LLC discontinue unsupported health benefit and personalization claims for its compounded tirzepatide products.